Skip to main content

XHANCE

Generic: fluticasone propionate

Verified·Oct 26, 2026
Manufacturer
Optinose
NDC
71715-003
RxCUI
1946583
Route
NASAL
ICD-10 indication
J32.9

Affordability Check

How much will you actually pay for XHANCE?

In 30 seconds, see every legitimate way to afford XHANCE — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About XHANCE

What is this medication? XHANCE is a prescription nasal spray containing fluticasone propionate, which is a type of medicine known as a corticosteroid. It features a specialized Exhalation Delivery System that sets it apart from conventional nasal sprays. To use it, a person blows into a mouthpiece while the spray is released into the nostril. This technique utilizes the air pressure from the breath to push the medication deep into the nasal cavities and sinus areas where inflammation often occurs.

The medication is primarily used to treat nasal polyps in adults and to manage the symptoms of chronic rhinosinusitis. By reducing inflammation in the nasal passages, it helps alleviate common issues like nasal congestion, facial pain, and a runny nose. Because it targets the underlying swelling associated with these conditions, it is intended for regular, daily use to achieve the best results in shrinking polyps and improving breathing.

Copay & patient assistance

  • Patient Copay Amount: As little as $0
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Patients must be commercially insured. Offer is not valid for patients enrolled in any government-funded prescription insurance program (e.g., Medicare, Medicaid).
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for XHANCE. Official source: DailyMed (NLM) · Label effective Jul 17, 2026

Indications and usage
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion itchy, watery eyes itchy nose runny nose sneezing
Dosage and administration
Directions read the Quick Start Guide for how to: prime the bottle use the spray clean the spray nozzle shake gently before each use use this product only once a day do not use more than directed ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER Week 1- use 2 sprays in each nostril once daily Week 2 through 6 months- use 1 or 2 sprays in each nostril once daily, as needed to treat your symptoms After 6 months of daily use – ask your doctor if you can keep using CHILDREN 4 TO 11 YEARS OF AGE the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief. Talk to your child’s doctor if your child needs to use the spray for longer than two months a year. an adult should supervise use use 1 spray in each nostril once daily CHILDREN UNDER 4 YEARS OF AGE do not use
Warnings
Warnings Only for use in the nose. Do not spray into your eyes or mouth.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How XHANCE appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

33%

1,791 of 5,499 plans

Most common tier

Tier 4

On 77% of covering formularies

Prior authorization required

66%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)18
17%
Tier 2 (generic)1
1%
Tier 3 (preferred brand)5
5%
Tier 4 (non-preferred brand)80
77%

Step therapy: 14% of formularies

Quantity limits: 88% of formularies

Coverage breadth: 104 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.